Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Emicizumab PUPs and Nuwiq ITI Study
NCT04030052 · Emory University · PHASE3 · withdrawn · last registry update 2024-01-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Emi PUPs and Nuwiq ITI study has been closed due to slow enrollment and study site startup.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F8 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-30Results posted on the registry: Spark Therapeutics, Inc., SPK-8011 (NCT03003533)
- 2024-12-18Phase 3 first posted: SK Plasma Co., Ltd., SKP-0141 (NCT06738901)
- 2024-12-17Phase 3 first posted: CSL Behring, Recombinant single-chain factor VIII (rVIII-SingleChain) (NCT06738485)
- 2024-12-13Also stopped (withdrawn): Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-12-04Phase 3 first posted: Swedish Orphan Biovitrum, Efanesoctocog alfa (NCT06716814)
- 2024-12-02Results posted on the registry: Takeda, TAK-672 (NCT04580407)
- 2024-10-31Results posted on the registry: Novo Nordisk A/S, turoctocog alfa pegol (NCT02137850)
- 2024-09-04Results posted on the registry: Eli Lilly and Company, SIG-001 (NCT04541628)
- 2024-09-04Also stopped (terminated): Eli Lilly and Company, SIG-001 (NCT04541628)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2024-04-04Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT04323098)
- 2024-03-07Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Recombinant human activated coagulation factor VIII for injection (NCT06297655)
- 2024-03-07Phase 3 first posted: Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-03-07Results posted on the registry: Baxalta now part of Shire, ADVATE (NCT04985682)
- 2024-02-13Results posted on the registry: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04759131)
- 2024-01-25Phase 3 first posted: BioMarin Pharmaceutical, Valoctocogene roxaparvovec (NCT06224907)
- 2024-01-18Results posted on the registry: Novo Nordisk A/S, turoctocog alfa pegol (N8-GP) (NCT05082116)
- 2024-01-12Phase 3 first posted: Unity Health Toronto, Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII (NCT06205095)
- 2023-12-05Phase 3 first posted: Chulalongkorn University, "Emicizumab", "HEMLIBRA®" (NCT06155955)
- 2023-11-28Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT03370913)
- 2023-11-21Phase 3 first posted: Hangzhou Gensciences Biopharmaceutical Co., Ltd., FRSW117 (NCT06142552)
- 2023-11-18Phase 3 first posted: AryoGen Pharmed Co., Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) (NCT06137092)
- 2023-11-01Phase 3 first posted: Shanghai Xinzhi BioMed Co., Ltd., Single dose intravenous injection of BBM-H803 (NCT06111638)
- 2023-10-25Results posted on the registry: Octapharma, Wilate (NCT04052698)
- 2023-06-28Results posted on the registry: Bayer, Damoctocog alfa pegol (Jivi, BAY94-9027) (NCT04085458)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision